Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
Clinical trial NCT06427330 · UNKNOWN
Trial details
- NCT number
- NCT06427330
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-02
- Primary completion
- 2025-06-30
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.